Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Diabetes Mellitus HELP
Based on 100,000 articles since 2006
|||| 27 

These are the 100000 published articles about Diabetes Mellitus that originated from Worldwide during 2006-2015.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Diagnosis and management of type 1 diabetes in adults: summary of updated NICE guidance. 2015

Amiel, Stephanie A / Pursey, Nancy / Higgins, Bernard / Dawoud, Dalia / Anonymous520944. ·Division of Diabetes and Nutritional Sciences, King's College London, London, UK. · National Clinical Guideline Centre, Royal College of Physicians, London NW1 4LE, UK nancy.pursey@rcplondon.ac.uk. · National Clinical Guideline Centre, Royal College of Physicians, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. · National Clinical Guideline Centre, Royal College of Physicians, Faculty of Pharmacy, Cairo University, Cairo, Egypt. · ·BMJ · Pubmed #26311706.

ABSTRACT: -- No abstract --

2 Guideline [Update on Current Care Guideline: Diabetic retinopathy]. 2015

Summanen, Paula / Kallioniemi, Vuokko / Komulainen, Jorma / Eriksson, Lars / Forsvik, Heikki / Hietala, Kustaa / Tulokas, Sirkku / Von Wendt, Gunvor / Anonymous2060811. · ·Duodecim · Pubmed #26237887.

ABSTRACT: Good treatment of diabetes decreases the risk of diabetic retinopathy. The goals of the treatment are adequate glucose balance, blood pressure and prevention of metabolic syndrome. Every patient with diabetes should regularly be screened for diabetic retinopathy. Timely and efficient treatment of retinopathy significantly decreases the risk of visual impairment.

3 Guideline Combined Diet and Physical Activity Promotion Programs for Prevention of Diabetes: Community Preventive Services Task Force Recommendation Statement. 2015

Pronk, Nicolaas P / Remington, Patrick L / Anonymous2140887. · ·Ann Intern Med · Pubmed #26168073.

ABSTRACT: DESCRIPTION: Community Preventive Services Task Force recommendation on the use of combined diet and physical activity promotion programs to reduce progression to type 2 diabetes in persons at increased risk. METHODS: The Task Force commissioned an evidence review that assessed the benefits and harms of programs to promote and support individual improvements in diet, exercise, and weight and supervised a review on the economic efficiency of these programs in clinical trial, primary care, and primary care-referable settings. POPULATION: Adolescents and adults at increased risk for progression to type 2 diabetes. RECOMMENDATION: The Task Force recommends the use of combined diet and physical activity promotion programs by health care systems, communities, and other implementers to provide counseling and support to clients identified as being at increased risk for type 2 diabetes. Economic evidence indicates that these programs are cost-effective.

4 Guideline A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. 2015

Huang, Enoch T / Mansouri, Jaleh / Murad, M Hassan / Joseph, Warren S / Strauss, Michael B / Tettelbach, William / Worth, Eugene R / Anonymous3140810. · ·Undersea Hyperb Med · Pubmed #26152105.

ABSTRACT: BACKGROUND: The role of hyperbaric oxygen (HBO2) for the treatment of diabetic foot ulcers (DFUs) has been examined in the medical literature for decades. There are more systematic reviews of the HBO2/DFU literature than there have been randomized controlled trials (RCTs), but none of these reviews has resulted in a clinical practice guideline (CPG) that clinicians, patients and policy-makers can use to guide decision-making in everyday practice. METHODS: The Undersea and Hyperbaric Medical Society (UHMS), following the methodology of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, undertook this systematic review of the HBO2 literature in order to rate the quality of evidence and generate practice recommendations for the treatment of DFUs. We selected four clinical questions for review regarding the role of HBO2 in the treatment of DFUs and analyzed the literature using patient populations based on Wagner wound classification and age of the wound (i.e., acute post-operative wound vs. non-healing wound of 30 or more days). Major amputation and incomplete healing were selected as critical outcomes of interest. RESULTS: This analysis showed that HBO2 is beneficial in preventing amputation and promoting complete healing in patients with Wagner Grade 3 or greater DFUs who have just undergone surgical debridement of the foot as well as in patients with Wagner Grade 3 or greater DFUs that have shown no significant improvement after 30 or more days of treatment. In patients with Wagner Grade 2 or lower DFUs, there was inadequate evidence to justify the use of HBO2 as an adjunctive treatment. CONCLUSIONS: Clinicians, patients, and policy-makers should engage in shared decision-making and consider HBO2 as an adjunctive treatment of DFUs that fit the criteria outlined in this guideline. The current body of evidence provides a moderate level of evidence supporting the use of HBO2 for DFUs. Future research should be directed at improving methods for patient selection, testing various treatment protocols and improving our confidence in the existing estimates.

5 Guideline TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. 2015

Freund, K Bailey / Korobelnik, Jean-François / Devenyi, Robert / Framme, Carsten / Galic, John / Herbert, Edward / Hoerauf, Hans / Lanzetta, Paolo / Michels, Stephan / Mitchell, Paul / Monés, Jordi / Regillo, Carl / Tadayoni, Ramin / Talks, James / Wolf, Sebastian. ·*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland. · ·Retina · Pubmed #26076215.

ABSTRACT: PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti-vascular endothelial growth factor agents, considering factors such as criteria for extension. RESULTS: A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography-guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti-vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. CONCLUSION: It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases.

6 Guideline Management of hyperosmolar hyperglycaemic state in adults with diabetes. 2015

Scott, A R / Anonymous1130989 / Anonymous1140989. ·Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. · ·Diabet Med · Pubmed #25980647.

ABSTRACT: Hyperglycaemic hyperosmolar state (HHS) is a medical emergency, which differs from diabetic ketoacidosis (DKA) and requires a different approach. The present article summarizes the recent guidance on HHS that has been produced by the Joint British Diabetes Societies for Inpatient Care, available in full at http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_HHS_Adults.pdf. HHS has a higher mortality rate than DKA and may be complicated by myocardial infarction, stroke, seizures, cerebral oedema and central pontine myelinolysis and there is some evidence that rapid changes in osmolality during treatment may be the precipitant of central pontine myelinolysis. Whilst DKA presents within hours of onset, HHS comes on over many days, and the dehydration and metabolic disturbances are more extreme. The key points in these HHS guidelines include: (1) monitoring of the response to treatment: (i) measure or calculate the serum osmolality regularly to monitor the response to treatment and (ii) aim to reduce osmolality by 3-8 mOsm/kg/h; (2) fluid and insulin administration: (i) use i.v. 0.9% sodium chloride solution as the principal fluid to restore circulating volume and reverse dehydration, (ii) fluid replacement alone will cause a fall in blood glucose (BG) level, (iii) withhold insulin until the BG level is no longer falling with i.v. fluids alone (unless ketonaemic), (iv) an initial rise in sodium level is expected and is not itself an indication for hypotonic fluids and (v) early use of insulin (before fluids) may be detrimental; and (3) delivery of care: (i) The diabetes specialist team should be involved as soon as possible and (ii) patients should be nursed in areas where staff are experienced in the management of HHS.

7 Guideline A guideline for the use of variable rate intravenous insulin infusion in medical inpatients. 2015

George, S / Dale, J / Stanisstreet, D / Anonymous1110989 / Anonymous1120989. ·Department of Diabetes and Endocrinology, East and North Herts NHS Trust, Lister Hospital, Stevenage, UK. · Dudley Group NHS Foundation Trust, Dudley, UK. · ·Diabet Med · Pubmed #25980646.

ABSTRACT: The present paper summarizes the key recommendations in a recent publication produced by the Joint British Diabetes Societies for Inpatient Care on the use of variable rate i.v. insulin infusion in 'medical' inpatients. The full guideline is available at http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_VRIII.pdf and is designed to be a practical guide that can used by any healthcare professional who manages medical inpatients with hyperglycaemia. Its main aim is to allow variable rate i.v. insulin infusion to be used safely, effectively and efficiently for this specific group of inpatients.

8 Guideline Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). 2015

Anonymous1160808. · ·Nephrol Dial Transplant · Pubmed #25940656.

ABSTRACT: -- No abstract --

9 Guideline Best practice for diabetic patients on hemodialysis 2012. 2015

Nakao, Toshiyuki / Inaba, Masaaki / Abe, Masanori / Kaizu, Kazo / Shima, Kenji / Babazono, Tetsuya / Tomo, Tadashi / Hirakata, Hideki / Akizawa, Tadao / Anonymous450896. ·Japanese Society for Dialysis Therapy, Tokyo, Japan. · ·Ther Apher Dial · Pubmed #25817932.

ABSTRACT: -- No abstract --

10 Guideline Standardized outcomes reporting in metabolic and bariatric surgery. 2015

Brethauer, Stacy A / Kim, Julie / El Chaar, Maher / Papasavas, Pavlos / Eisenberg, Dan / Rogers, Ann / Ballem, Naveen / Kligman, Mark / Kothari, Shanu / Anonymous670905. ·Bariatric and Metabolic Center, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Ave., M61, Cleveland, OH, 44195, USA, brethas@ccf.org. · ·Obes Surg · Pubmed #25802064.

ABSTRACT: -- No abstract --

11 Guideline The 2015 standards for diabetes care: maintaining a patient-centered approach. 2015

Romeo, Giulio R / Abrahamson, Martin J. · ·Ann Intern Med · Pubmed #25798733.

ABSTRACT: -- No abstract --

12 Guideline ISFM consensus guidelines on the practical management of diabetes mellitus in cats. 2015

Sparkes, Andrew H / Cannon, Martha / Church, David / Fleeman, Linda / Harvey, Andrea / Hoenig, Margarethe / Peterson, Mark E / Reusch, Claudia E / Taylor, Samantha / Rosenberg, Dan / Anonymous6860804. ·International Cat Care/ISFM, Tisbury, Wiltshire SP3 6LD, UK andy@icatcare.org. · Oxford Cat Clinic, Oxford OX2 9JU, UK. · Professor, Small Animal Medicine and Surgery Group, The Royal Veterinary College, North Mymms, Hatfield, Hertfordshire AL9 7TA, UK. · Animal Diabetes Australia, Rowville Veterinary Clinic, Rowville, VIC 3178, Australia. · Small Animal Specialist Hospital, North Ryde, NSW 2113, Australia. · Professor, Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana-Champaign, Illinois, USA. · Animal Endocrine Clinic, 21 West 100th Street, New York, NY 10025, USA. · Professor & Director, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland. · International Cat Care/ISFM, Tisbury, Wiltshire SP3 6LD, UK. · Micen Vet Centre, 58 Rue Auguste Perret, Parc Technologique, Europarc, 9400 Créteil, France. · ·J Feline Med Surg · Pubmed #25701862.

ABSTRACT: PRACTICAL RELEVANCE: Diabetes mellitus (DM) is a common endocrinopathy in cats that appears to be increasing in prevalence. The prognosis for affected cats can be good when the disease is well managed, but clinical management presents challenges, both for the veterinary team and for the owner. These ISFM Guidelines have been developed by an independent, international expert panel of clinicians and academics to provide practical advice on the management of routine (uncomplicated) diabetic cats. CLINICAL CHALLENGES: Although the diagnosis of diabetes is usually straightforward, optimal management can be challenging. Clinical goals should be to limit or eliminate clinical signs of the disease using a treatment regimen suitable for the owner, and to avoid insulin-induced hypoglycaemia or other complications. Optimising bodyweight, feeding an appropriate diet and using a longer acting insulin preparation (eg, protamine zinc insulin, insulin glargine or insulin detemir) are all factors that are likely to result in improved glycaemic control in the majority of cats. There is also some evidence that improved glycaemic control and reversal of glucose toxicity may promote the chances of diabetic remission. Owner considerations and owner involvement are an important aspect of management. Provided adequate support is given, and owners are able to take an active role in monitoring blood glucose concentrations in the home environment, glycaemic control may be improved. Monitoring of other parameters is also vitally important in assessing the response to insulin. Insulin adjustments should always be made cautiously and not too frequently--unless hypoglycaemia is encountered. EVIDENCE BASE: The Panel has produced these Guidelines after careful review of the existing literature and of the quality of the published studies. They represent a consensus view on practical management of cats with DM based on available clinical data and experience. However, in many areas, substantial data are lacking and there is a need for better studies in the future to help inform and refine recommendations for the clinical management of this common disease.

13 Guideline Diabetes UK Position Statement. Competency frameworks in diabetes. 2015

Simmons, D / Deakin, T / Walsh, N / Turner, B / Lawrence, S / Priest, L / George, S / Vanterpool, G / McArdle, J / Rylance, A / Terry, G / Little, P / Anonymous570946. ·Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · ·Diabet Med · Pubmed #25611804.

ABSTRACT: The quality, skills and attitudes of staff working in the healthcare system are central to multidisciplinary learning and working, and to the delivery of the quality of care patients expect. Patients want to know that the staff supporting them have the right knowledge and attitudes to work in partnership, particularly for conditions such as diabetes where 95% of all care is delivered by the person with diabetes themselves. With the current changes in the NHS structures in England, and the potential for greater variation in the types of 'qualified provider', along with the recent scandal at Mid-Staffordshire Hospital, staff need to be shown to be competent and named/accredited or recognized as such. This will help to restore faith in an increasingly devolved delivery structure. The education and validation of competency needs to be consistently delivered and assured to ensure standards are maintained for different roles and disciplines across each UK nation. Diabetes UK recommends that all NHS organizations prioritize healthcare professional education, training and competency through the implementation of a National Diabetes Competency Framework and the phased approach to delivery to address this need.

14 Guideline (14) Diabetes advocacy. 2015

Anonymous3980801. · ·Diabetes Care · Pubmed #25537716.

ABSTRACT: -- No abstract --

15 Guideline (13) Diabetes care in the hospital, nursing home, and skilled nursing facility. 2015

Anonymous3970801. · ·Diabetes Care · Pubmed #25537715.

ABSTRACT: -- No abstract --

16 Guideline (2) Classification and diagnosis of diabetes. 2015

Anonymous3960801. · ·Diabetes Care · Pubmed #25537714.

ABSTRACT: -- No abstract --

17 Guideline (12) Management of diabetes in pregnancy. 2015

Anonymous3950801. · ·Diabetes Care · Pubmed #25537713.

ABSTRACT: -- No abstract --

18 Guideline (11) Children and adolescents. 2015

Anonymous3940801. · ·Diabetes Care · Pubmed #25537712.

ABSTRACT: -- No abstract --

19 Guideline (10) Older adults. 2015

Anonymous3930801. · ·Diabetes Care · Pubmed #25537711.

ABSTRACT: -- No abstract --

20 Guideline (9) Microvascular complications and foot care. 2015

Anonymous3920801. · ·Diabetes Care · Pubmed #25537710.

ABSTRACT: -- No abstract --

21 Guideline (1) Strategies for improving care. 2015

Anonymous3910801. · ·Diabetes Care · Pubmed #25537709.

ABSTRACT: -- No abstract --

22 Guideline (8) Cardiovascular disease and risk management. 2015

Anonymous3900801. · ·Diabetes Care · Pubmed #25537708.

ABSTRACT: -- No abstract --

23 Guideline (7) Approaches to glycemic treatment. 2015

Anonymous3890801. · ·Diabetes Care · Pubmed #25537707.

ABSTRACT: -- No abstract --

24 Guideline (6) Glycemic targets. 2015

Anonymous3870801. · ·Diabetes Care · Pubmed #25537705.

ABSTRACT: -- No abstract --

25 Guideline (5) Prevention or delay of type 2 diabetes. 2015

Anonymous3860801. · ·Diabetes Care · Pubmed #25537704.

ABSTRACT: -- No abstract --